相关实验视频

Updated: Jul 2, 2025

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

在深静脉血栓症患者中使用静止素和死亡率. 来自RIETE注册表的数据

Carmine Siniscalchi¹, Behnood Bikdeli², David Jiménez³

¹Department of Angiology, Azienda Ospedaliera Universitaria, Parma, Italy.

Thrombosis research

|February 28, 2024

概括

在患有深静脉血栓症 (DVT) 的患者中,使用他与较低的死亡风险有关. 这项研究发现,与非使用者相比,他类药物使用者的3个月死亡率显著降低.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
流行病学流行病学

背景情况:

对于静脉深血栓症 (DVT) 患者的死亡率,他类药物治疗的影响仍未得到充分研究.
深静脉血栓症 (DVT) 是致病率和死亡率的一个重要原因.

研究的目的:

评估在被诊断为孤立深静脉血栓症 (DVT) 的患者中,他类药物使用与3个月死亡率之间的关联.

主要方法:

利用RIETE注册表的数据,包括从2009年1月到2022年4月的46,440名患有孤立DVT的患者.
采用混合效应的生存模型来分析3个月后他类药物使用和全因死亡率之间的关联,调整临床共变量和中心聚类.

主要成果:

静止剂使用者 (21%) 年龄较大,并比不使用者有更多的并发症.
三个月的全因死亡率在非使用者中为5.8%,在他类药物使用者中为6.0%.
多变量分析显示,他类药物使用者因各种原因死亡的调整后危险比率 (aHR) 显着较低 (aHR:0.77;95% CI:0.69-0.86).
这种降低的风险在不同DVT位置和特定的他类药物 (西姆瓦斯塔丁,阿托瓦斯塔丁,罗斯瓦斯塔丁) 中一致.
主要出血事件没有显示与他类药物使用的关联,作为伪造终点.

结论:

在患有孤立深静脉血栓症 (DVT) 的患者中,使用他与3个月死亡风险显著降低有关.
这些发现表明,在治疗DVT患者时,他类药物可能具有保护作用.

关键词:

流血出血流血出血死亡死亡死亡死亡死亡死亡死亡死亡深静脉血栓形成的原因是深静脉血栓.史塔丁类药物是一种静脉血栓塞栓症是一种静脉血栓塞栓症.

更多相关视频

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis

Published on: December 22, 2017

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...